Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:37:47 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:IOVA from 2023-04-30 to 2024-04-29 - 39 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 16:01U:IOVANews ReleaseIovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
2024-04-19 17:15U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-22 17:31U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-04 06:30U:IOVANews ReleaseIovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
2024-03-01 17:00U:IOVANews ReleaseIovance Biotherapeutics to Present at Upcoming Conferences
2024-02-28 16:02U:IOVANews ReleaseIovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
2024-02-22 08:45U:IOVANews ReleaseIovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
2024-02-20 06:30U:IOVANews ReleaseIovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
2024-02-16 17:31U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-02-16 15:39U:IOVANews ReleaseIovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
2024-02-16 15:20U:IOVANews ReleaseIovance ¢ € ™s AMTAGVI ¢ „ ¢ ‚  (lifileucel) Receives U.S. FDA Accelerated Approval ‚  for Advanced Melanoma
2024-01-19 17:15U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-12-27 07:00U:IOVANews ReleaseIovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
2023-12-22 17:15U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-11-17 17:00U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-11-07 16:01U:IOVANews ReleaseIovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
2023-10-31 16:01U:IOVANews ReleaseIovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
2023-10-31 09:05U:IOVANews ReleaseIovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer ¢ € ™s (SITC) 38th Annual Meeting
2023-10-20 17:15U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-10-16 08:15U:IOVANews ReleaseIovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
2023-09-27 16:01U:IOVANews ReleaseIovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer ¢ € ™s (SITC) 38th Annual Meeting
2023-09-22 18:25U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-09-14 18:10U:IOVANews ReleaseU.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
2023-09-07 07:31U:IOVANews ReleaseIovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
2023-08-18 17:00U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-08-08 16:01U:IOVANews ReleaseIovance Biotherapeutics Reports Second Quarter and First Half 2023 ‚  Financial Results and Corporate Updates
2023-07-25 16:01U:IOVANews ReleaseIovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
2023-07-24 16:02U:IOVANews ReleaseIovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
2023-07-21 17:34U:IOVANews ReleaseIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-07-13 16:01U:IOVANews ReleaseIovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
2023-07-10 21:46U:IOVANews ReleaseIovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
2023-07-10 16:35U:IOVANews ReleaseIovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
2023-07-10 07:00U:IOVANews ReleaseIovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
2023-06-20 07:01U:IOVANews ReleaseIovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
2023-06-15 07:01U:IOVANews ReleaseIovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
2023-06-09 07:01U:IOVANews ReleaseIovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
2023-05-26 17:31U:IOVANews ReleaseIovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
2023-05-09 16:02U:IOVANews ReleaseIovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
2023-05-02 16:01U:IOVANews ReleaseIovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023